Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Session VI: Rare GI Tumors: NETs, GISTs, and Anal cancer

SO-12: Updated safety, efficacy and PK results from an open-label, multicenter, phase I/II study of avapritinib in Chinese patients with unresectable or metastatic gastrointestinal stromal tumors (GIST)

Date

01 Jul 2021

Session

Session VI: Rare GI Tumors: NETs, GISTs, and Anal cancer

Presenters

Jian Li, China (People's Republic)

Resources

Login to access the resources on OncologyPRO.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings